Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum PsyBio Therapeutics Corp V.PSYB.H

Alternate Symbol(s):  PSYBF

PsyBio Therapeutics Corp. is a Canada-based biotechnology company. The Company is focused on discovering, designing and developing psycho-focused therapeutics to improve mental and neurological conditions. It is focused on understanding the value of tryptamines and other related psycho-targeted molecules as therapeutic candidates to improve mental and neurological health. The Company is engaged... see more

TSXV:PSYB.H - Post Discussion

PsyBio Therapeutics Corp > Time to Nibble at More Shares?
View:
Post by PuerSimia on Mar 23, 2021 2:08pm

Time to Nibble at More Shares?

Bookworm, we are at .38 cdn today. I bought a few more shares, but starting to have second thoughts about it being a good idea. Today's news release should have supported the price, not pushed it down, don't you think? This is a weird one.
Comment by ValueValue123 on Mar 23, 2021 3:22pm
Based on my review of PSYB and its peers (FTRP, CYBN, NUMI, etc.), this seems tremendosuly undervlaued (~C$40m comapred to C$200m+). The RTO financing was done at C$0.35 per share with a raise of C$14.5m, and based on the fact that various publications are highlighing PSYB's annoucement on Berekely Lab from today and Albany Molecular a few weeks back I have no doubt they will continue to ...more  
Comment by Bookworm28 on Mar 23, 2021 10:06pm
You're not the only one scratching their head PuerSimia. I agree with ValueValue123's comment about the stock being totally undervalued compared to their peers. Looking at the trading data, my current theory is selling by old timers from Leo Acquisitions who paid nothing for their shares, maybe some selling from the guys who participated in the IPO, and no buyers. They're in serious ...more  
Comment by ValueValue123 on Mar 24, 2021 12:54am
So far PSYB's operaitonal press release have been substantive compare to what other are putting out. Agreed?  Psilocybin w. Albany Molecular (March 3):https://financialpost.com/globe-newswire/psybio-therapeutics-initiates-pilot-scale-development-of-proprietary-biosynthetic-psilocybin-with-global-contract-research-development-and-manufacturing-organization Norbaeocystin w. Berkely Lab ...more  
Comment by Bookworm28 on Mar 24, 2021 3:29pm
Hmmm, I liked the share price better before they started telling their story. .365 today is not doing much for my confidence.
Comment by Bookworm28 on Mar 24, 2021 5:07pm
What do you guys figure? We at the bottom yet?
Comment by PuerSimia on Mar 24, 2021 10:44pm
I think we might test .33 again in the next couple of days.
Comment by Bookworm28 on Mar 30, 2021 9:31pm
Good call PuerSimia. Did you get some at .33? I picked up some BLDP, as you recommended. Popped in and out for some easy money today. Thanks.
Comment by PuerSimia on Mar 31, 2021 11:02pm
Sure did. Not too much for sale, but that's OK.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities